# C_2014287EN.01000301.xml

| 28.8.2014 | EN | Official Journal of the European Union | C 287/3 |
| --- | --- | --- | --- |

28.8.2014

EN

Official Journal of the European Union

C 287/3

---

Prior notification of a concentration

(Case M.7346 — Montagu Funds/Astorg Funds/Diacine France)

Candidate case for simplified procedure

(Text with EEA relevance)

2014/C 287/04

| 1. | On 19 August 2014, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Montagu funds and Astorg funds respectively managed and controlled by the undertakings Montagu Private Equity SAS (‘Montagu’, France), controlled by Montagu Private Equity LLP (United Kingdom), and Astorg Partners SAS (‘Astorg’, France) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Diacine France SAS (‘Diacine France’, France), by way of purchase of shares and securities. |
| --- | --- |

1.

On 19 August 2014, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Montagu funds and Astorg funds respectively managed and controlled by the undertakings Montagu Private Equity SAS (‘Montagu’, France), controlled by Montagu Private Equity LLP (United Kingdom), and Astorg Partners SAS (‘Astorg’, France) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Diacine France SAS (‘Diacine France’, France), by way of purchase of shares and securities.

1

| 2. | The business activities of the undertakings concerned are the following:
  —   Montagu: French fund manager controlling several companies active within a broad range of industry sectors, including notably used car valuation, manufacture of margarine, healthcare and education,
  —   Astorg: independent private equity firm incorporated under French law, which manages funds investing in a broad range of industries, such as healthcare, the manufacturing of glass bottles, cements or insurance brokerage,
  —   Diacine France: holding company of Sebia SA, an in vitro diagnostics specialty company developing innovative diagnostics solutions for biologists and physicians in the fields of oncology, haemoglobin disorders and other metabolic disorders including diabetes. |
| --- | --- |

2.

The business activities of the undertakings concerned are the following:

—   Montagu: French fund manager controlling several companies active within a broad range of industry sectors, including notably used car valuation, manufacture of margarine, healthcare and education,

Montagu

—   Astorg: independent private equity firm incorporated under French law, which manages funds investing in a broad range of industries, such as healthcare, the manufacturing of glass bottles, cements or insurance brokerage,

Astorg

—   Diacine France: holding company of Sebia SA, an in vitro diagnostics specialty company developing innovative diagnostics solutions for biologists and physicians in the fields of oncology, haemoglobin disorders and other metabolic disorders including diabetes.

Diacine France

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

2

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7346 — Montagu Funds/Astorg Funds/Diacine France, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7346 — Montagu Funds/Astorg Funds/Diacine France, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---